Both coprimary endpoints were statistically significantly better in Clobetasol Propionate Ophthalmic Suspension 0.05%-treated patients compared with vehicle-treated patients. The Food and Drug ...

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Clobetasol propionate ophthalmic suspension 0.05% was ...

CORAL GABLES, Fla.--(BUSINESS WIRE)--Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced that the U.S. Food and Drug ...

Clobetasol propionate 0.05%; crm. Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use ...

Taiwan-based Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Apotex for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic ...

MUMBAI, India Glenmark Pharmaceuticals has begun marketing and distributing five Clobetasol Propionate dermatology products, according to published reports. Glenmark acquired the rights for the drugs ...

ALLEGAN -- Perrigo Co. (Nasdaq: PRGO; TASE) announced that it has agreed to settle its Hatch-Waxman litigation relating to Clobetasol propionate emulsion foam, 0.05% brought by Stiefel Research ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...